Transcept Pharmaceuticals Inc. rejected an unsolicited offer from Martin Shkreli's Retrophin Inc., the drug developer said Wednesday, as it licensed a migraine drug from a Japanese company.
Richmond-based Transcept (NASDAQ: TSPT) said in a press release that the $4-per-share offer is "not in the best interests of Transcept or its shareholders." It marks the second rebuff of the company founded by Shkreli, a 30-year-old health care hedge fund manager and activist shareholder.
Help employers find you! Check out all the jobs and post your resume.
